Sage Therapeutics Stock Soars as Biogen Makes Unsolicited Takeover Bid

Investopedia

01-13

Key Takeaways

Sage Therapeutics reported that Biogen made an unsolicited offer to purchase all of the shares of the biopharmaceutical firm it doesn't already own.
The bid of $7.22 per share was a 30% premium to Sage's closing price on Friday.
Biogen already owns a 10.2% stake in Sage.

Sage Therapeutics (SAGE) shares soared nearly 40% Monday on news Biogen (BIIB) is offering to buy the rest of the Sage stock it doesn't already own for $7.22 per share.

The unsolicited, non-binding proposal was a 30% premium over Sage’s Friday closing price of $5.55.

The biopharmaceutical firm said its board "will carefully review and evaluate the proposal made by Biogen to determine the course of action that it believes is in the best interest of the Company and all Sage shareholders."

Biogen Owns 10.2% Stake in Sage

According to a regulatory filing, Biogen owns 6.24 million shares of Sage, equal to a 10.2% stake.

The bid came just as both companies were set to make presentations at this year's J.P. Morgan Healthcare conference in San Francisco.

Despite today's big jump, shares of Sage Therapeutics have lost nearly three-quarters of their value over the past year. Biogen shares slipped less than 1% Monday morning.

TradingView

Do you have a news tip for Investopedia reporters? Please email us at

tips@investopedia.com

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2503589820"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2503589820\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2503589820?lang=zh_CN&edition=fundamental","thumbnail":"https://www.investopedia.com/thmb/q9_MAdxlQyU1CGKdgYB_VgASepU=/2872x1915/filters:no_upscale():max_bytes(150000):strip_icc()/GettyImages-1742678123-25d92008a8844f64a3b09d5739a8612f.jpg","is_english":true,"pubTime":"2025-01-13 22:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2503589820","market":"sg","top_or_hot":-1,"title":"Sage Therapeutics Stock Soars as Biogen Makes Unsolicited Takeover Bid","media":"Investopedia","content":"<html><body><div><div><div><h3>Key Takeaways</h3>\n<div><ul><li><a href=\"https://laohu8.com/S/SAGE\">Sage Therapeutics</a> reported that Biogen made an unsolicited offer to purchase all of the shares of the biopharmaceutical firm it doesn't already own.</li><li>The bid of $7.22 per share was a 30% premium to Sage's closing price on Friday.</li><li>Biogen already owns a 10.2% stake in Sage.</li></ul></div></div></div>\n<p> Sage <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (SAGE) shares soared nearly 40% Monday on news Biogen (BIIB) is offering to buy the rest of the Sage stock it doesn't already own for $7.22 per share.<span></span>\n</p>\n<div></div>\n<p> The unsolicited, non-binding proposal was a 30% premium over Sage’s Friday closing price of $5.55.\n</p>\n<div></div>\n<p> The biopharmaceutical firm said its board \"will carefully review and evaluate the proposal made by Biogen to determine the course of action that it believes is in the best interest of the Company and all Sage shareholders.\"\n</p>\n<div></div>\n<span></span><h2> <span> Biogen Owns 10.2% Stake in Sage </span> </h2>\n<p> According to a regulatory filing, Biogen owns 6.24 million shares of Sage, equal to a 10.2% stake.<span></span>\n</p>\n<div></div>\n<p> The bid came just as both companies were set to make presentations at this year's J.P. Morgan Healthcare conference in San Francisco.<span></span>\n</p>\n<div></div>\n<p> Despite today's big jump, shares of Sage Therapeutics have lost nearly three-quarters of their value over the past year. Biogen shares slipped less than 1% Monday morning.\n</p>\n<div></div>\n<figure> <div>\n<div>\n<img height=\"811\" width=\"1542\"/>\n<noscript>\n<img height=\"811\" sizes=\"750px\" src=\"https://www.investopedia.com/thmb/JT4Byri3xjsY5Go2e7dJMU06Ef8=/1500x0/filters:no_upscale():max_bytes(150000):strip_icc()/SAGE_2025-01-13_09-34-27-5507f125057c4736a6c73d8fdd78e7bc.png\" srcset=\"https://www.investopedia.com/thmb/Xi7IbI4pjCDujuyIgaRQd5zBzyw=/750x0/filters:no_upscale():max_bytes(150000):strip_icc()/SAGE_2025-01-13_09-34-27-5507f125057c4736a6c73d8fdd78e7bc.png 750w\" width=\"1542\"/>\n</noscript>\n</div> </div>\n<figcaption> <span><p>TradingView</p></span>\n</figcaption></figure>\n<div><div>Do you have a news tip for Investopedia reporters? Please email us at</div>\n<span>tips@investopedia.com</span></div></div></body></html>","source":"investopedia_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sage Therapeutics Stock Soars as Biogen Makes Unsolicited Takeover Bid</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSage Therapeutics Stock Soars as Biogen Makes Unsolicited Takeover Bid\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-01-13 22:51 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.investopedia.com/sage-therapeutics-stock-soars-as-biogen-makes-unsolicited-takeover-bid-8773323><strong>Investopedia</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Key Takeaways\nSage Therapeutics reported that Biogen made an unsolicited offer to purchase all of the shares of the biopharmaceutical firm it doesn't already own.The bid of $7.22 per share was a 30% ...</p>\n\n<a href=\"https://www.investopedia.com/sage-therapeutics-stock-soars-as-biogen-makes-unsolicited-takeover-bid-8773323\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://www.investopedia.com/sage-therapeutics-stock-soars-as-biogen-makes-unsolicited-takeover-bid-8773323","article_id":"2503589820","we_media_id":null,"thumbnails":["https://www.investopedia.com/thmb/q9_MAdxlQyU1CGKdgYB_VgASepU=/2872x1915/filters:no_upscale():max_bytes(150000):strip_icc()/GettyImages-1742678123-25d92008a8844f64a3b09d5739a8612f.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2503589820","pubTimestamp":1736779881,"columns":[],"sourceInfo":{"source_id":"investopedia_highlight","name":"Investopedia"},"weMediaInfo":null,"summary":"Sage Therapeutics reported that Biogen made an unsolicited offer to purchase all of the shares of the biopharmaceutical firm it doesn't already own.The bid of $7.22 per share was a 30% premium to Sage's closing price on Friday.Biogen already owns a 10.2% stake in Sage.Sage Therapeutics  shares soared nearly 40% Monday on news Biogen  is offering to buy the rest of the Sage stock it doesn't already own for $7.22 per share.The unsolicited, non-binding proposal was a 30% premium over Sage’s Friday closing price of $5.55.The biopharmaceutical firm said its board \"will carefully review and evaluate the proposal made by Biogen to determine the course of action that it believes is in the best interest of the Company and all Sage shareholders.\". According to a regulatory filing, Biogen owns 6.24 million shares of Sage, equal to a 10.2% stake.Despite today's big jump, shares of Sage Therapeutics have lost nearly three-quarters of their value over the past year. Biogen shares slipped less than 1","collect":0,"end_time":0,"defaultTopTitle":"investopedia.com","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"Biogen主动提出收购要约，Sage Therapeutics股价飙升","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BIIB":1,"SAGE":1},"content_text":"Key Takeaways\nSage Therapeutics reported that Biogen made an unsolicited offer to purchase all of the shares of the biopharmaceutical firm it doesn't already own.The bid of $7.22 per share was a 30% premium to Sage's closing price on Friday.Biogen already owns a 10.2% stake in Sage.\n Sage Therapeutics (SAGE) shares soared nearly 40% Monday on news Biogen (BIIB) is offering to buy the rest of the Sage stock it doesn't already own for $7.22 per share.\n\n\n The unsolicited, non-binding proposal was a 30% premium over Sage’s Friday closing price of $5.55.\n\n\n The biopharmaceutical firm said its board \"will carefully review and evaluate the proposal made by Biogen to determine the course of action that it believes is in the best interest of the Company and all Sage shareholders.\"\n\n\n  Biogen Owns 10.2% Stake in Sage  \n According to a regulatory filing, Biogen owns 6.24 million shares of Sage, equal to a 10.2% stake.\n\n\n The bid came just as both companies were set to make presentations at this year's J.P. Morgan Healthcare conference in San Francisco.\n\n\n Despite today's big jump, shares of Sage Therapeutics have lost nearly three-quarters of their value over the past year. Biogen shares slipped less than 1% Monday morning.\n\n\n \n\n\n\n\n\n \n TradingView\n\nDo you have a news tip for Investopedia reporters? Please email us at\ntips@investopedia.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}